Margaret Rosenfeld, M.D., M.P.H., of Seattle Children's Hospital, and professionals conducted research to examine if hypertonic saline would scale back the rate of pulmonary exacerbations in children younger than 6 years of age with cystic fibrosis (CF). Inhaled hypertonic saline is usually recommended as therapy for affected individuals 6 years or older by using CF, but its effectiveness has not been tested in affected individuals younger than 6 years. In the randomized trial, the lively therapy group acquired 7% hypertonic saline as well as the control group (n = 163) acquired 0.9 percent isotonic saline, nebulized (dispensed in a fine mist) twice on the daily basis for 48 weeks.
The scientists discovered that the typical pulmonary exacerbation rate ended up being same between both individual groups. "Hypertonic saline did not decrease the rate of pulmonary exacerbations in these little ones. Moreover, hypertonic saline did not show any major consequences on secondary end points such as weight, height, respiratory rate, oxygen saturation, anti-biotic use, or parent describe of respiratory symptoms and signs."
No comments:
Post a Comment